JP2941787B2 - Pharmaceutical composition and health food containing polyunsaturated fatty acid - Google Patents
Pharmaceutical composition and health food containing polyunsaturated fatty acidInfo
- Publication number
- JP2941787B2 JP2941787B2 JP10177056A JP17705698A JP2941787B2 JP 2941787 B2 JP2941787 B2 JP 2941787B2 JP 10177056 A JP10177056 A JP 10177056A JP 17705698 A JP17705698 A JP 17705698A JP 2941787 B2 JP2941787 B2 JP 2941787B2
- Authority
- JP
- Japan
- Prior art keywords
- arachidonic acid
- pharmaceutical composition
- health food
- acid
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、比較的多量の多価
不飽和脂肪酸を含有する油脂を必須成分として配合して
なる、糖尿病および肝ガンの予防または治療に有効な医
薬組成物および健康食品に関する。The present invention relates to a pharmaceutical composition and a health food which are effective in preventing or treating diabetes and liver cancer, comprising an oil or fat containing a relatively large amount of polyunsaturated fatty acid as an essential component. About.
【０００２】[0002]
【従来の技術】アラキドン酸はプロスタグランジンの生
物学的前駆体であり、最近、その薬理効果が注目されて
いる。アラキドン酸は、生体内では、リノール酸から、
γ−リノレン酸、ジホモ−γ−リノレン酸を経て合成さ
れるが、この合成アラキドン酸がプロスタグランジンに
変換され、これが効果を発揮するものと考えられてい
る。したがって、アラキドン酸やその生合成原料たるリ
ノール酸を医薬や、健康食品の有効成分とすることが提
案されている。例えば、特開昭５９−６２５２２号に
は、リノール酸やアラキドン酸を界面活性剤と共に水溶
性の組成物として経口投与し、消化器系障害の予防や治
療に用いることが提案されている。2. Description of the Related Art Arachidonic acid is a biological precursor of prostaglandin, and its pharmacological effect has recently attracted attention. Arachidonic acid is derived from linoleic acid in vivo,
It is synthesized via γ-linolenic acid and dihomo-γ-linolenic acid, and this synthetic arachidonic acid is converted to prostaglandin, which is considered to exert its effect. Therefore, it has been proposed that arachidonic acid and linoleic acid, which is a biosynthetic raw material thereof, be used as an active ingredient of a medicine or health food. For example, Japanese Patent Application Laid-Open No. 59-62522 proposes that linoleic acid and arachidonic acid be orally administered together with a surfactant as a water-soluble composition and used for prevention and treatment of digestive disorders.
【０００３】上述のリノール酸は通常の油脂食品中に多
量に含有されており、その入手は容易で、食物としての
摂取によって所望の効果を期待できるものの、アラキド
ン酸は魚や肉、卵等の食品に少量含有されているにすぎ
ず、その薬理効果を期待できる十分な量を安価に入手す
ることは困難である。また、特開昭５９−６２５２２号
では、精製された遊離脂肪酸形態のアラキドン酸を使用
しているが、これは高価であるので、実用的ではない。[0003] The above-mentioned linoleic acid is contained in large amounts in ordinary fats and oils foods, and it is easy to obtain it, and desired effects can be expected by ingesting it as food, but arachidonic acid is used in foods such as fish, meat and eggs. However, it is difficult to obtain inexpensively a sufficient amount that can expect its pharmacological effect. Japanese Patent Application Laid-Open No. 59-62522 uses arachidonic acid in the form of a purified free fatty acid, but this is not practical because it is expensive.
【０００４】また、最近、多価不飽和脂肪酸と肝疾患と
の関係についても研究がなされてきており、例えば、Ph
arma Media、Vol.14(1996)148-165には、アラキドン
酸、リノール酸、γ−リノレン酸などの多価不飽和脂肪
酸の補給が、肝硬変、肝ガンなどの疾患あるいはインス
リン抵抗性に及ぼす影響が示されている。しかしなが
ら、かかる報告は未だ実証段階に至るものではない。[0004] Recently, researches have also been conducted on the relationship between polyunsaturated fatty acids and liver diseases.
arma Media, Vol. 14 (1996) 148-165, describes the effects of supplementation of polyunsaturated fatty acids such as arachidonic acid, linoleic acid, and γ-linolenic acid on diseases such as cirrhosis, liver cancer, and insulin resistance. It is shown. However, such a report has not yet reached the demonstration stage.
【０００５】[0005]
【発明が解決しようとする課題】このような事情に鑑
み、本発明者らは糖尿病および肝ガンの予防・治療に有
効な医薬品または実用的な健康食品を得るべく鋭意研究
を行った結果、例えば、特開昭６３−４４８９１号や特
開平２−８６７８９号などに開示されるような微生物学
的方法により得られる高濃度のアラキドン酸を含有する
油脂がその目的に好適であり、そのような油脂を配合し
た医薬組成物および健康食品が実用的であり、その摂取
が、糖尿病や肝ガンの予防・治療に有効であることを実
証により見い出し、本発明を完成するに至った。In view of such circumstances, the present inventors have conducted intensive studies to obtain a drug or a practical health food effective for the prevention and treatment of diabetes and liver cancer. Fats and oils containing a high concentration of arachidonic acid obtained by microbiological methods as disclosed in JP-A-63-44891 and JP-A-2-86789 are suitable for the purpose. A pharmaceutical composition and a health food containing the compound are practical and found to be effective in preventing and treating diabetes and liver cancer, and have completed the present invention.
【０００６】[0006]
【課題を解決するための手段】すなわち、本発明は、そ
の第１の態様として、アラキドン酸含有油脂、あるいは
さらにドコサヘキサエン酸含有油脂やカキ肉エキスを必
須成分としてなることを特徴とする糖尿病および肝ガン
の予防・治療用の医薬組成物を提供するものである。ま
た、本発明は、その第２の態様として、アラキドン酸含
有油脂、あるいはさらにドコサヘキサエン酸含有油脂や
カキ肉エキスを必須成分としてなることを特徴とする糖
尿病および肝ガンの予防・治療用の健康食品を提供する
ものである。本発明によれば、糖尿病および肝ガンなど
の肝疾患を実用的かつ有効に予防・治療し得る。That is, the first aspect of the present invention relates to diabetes and liver comprising arachidonic acid-containing oil or fat, or docosahexaenoic acid-containing oil or oyster meat extract as essential components. It is intended to provide a pharmaceutical composition for preventing or treating cancer. In a second aspect of the present invention, there is provided a health food for preventing and treating diabetes and liver cancer, characterized by comprising arachidonic acid-containing oil or fat, or docosahexaenoic acid-containing oil or oyster meat extract as an essential component. Is provided. According to the present invention, liver diseases such as diabetes and liver cancer can be practically and effectively prevented and treated.
【０００７】[0007]
【発明の実施の形態】本発明で用いるアラキドン酸含有
油脂は、特に限定されるものではないが、アラキドン酸
生産能を有する微生物から得られるアラキドン酸含有油
脂、すなわち、油脂全体に対してアラキドン酸含有量が
２重量％以上、好ましくは１０〜９９重量％、さらに好
ましくは２０〜９９重量％の油脂である。アラキドン酸
の摂取量が少なすぎると、その効果が期待できないの
で、かかる油脂は、アラキドン酸含有量が、医薬組成物
または食品全体に対して２重量％以上、好ましくは１０
重量％以上となるように配合する。BEST MODE FOR CARRYING OUT THE INVENTION The arachidonic acid-containing oil and fat used in the present invention is not particularly limited, but arachidonic acid-containing oil and fat obtained from a microorganism having arachidonic acid-producing ability, that is, arachidonic acid relative to the whole oil and fat. Fats and oils having a content of 2% by weight or more, preferably 10 to 99% by weight, more preferably 20 to 99% by weight. If the intake of arachidonic acid is too small, its effect cannot be expected. Therefore, such fats and oils have an arachidonic acid content of 2% by weight or more, preferably 10% by weight, based on the whole pharmaceutical composition or food.
It is blended so as to be at least% by weight.
【０００８】このような比較的高濃度のアラキドン酸を
含有する油脂は、例えば、特開昭６３−４４８９１号に
開示の方法に従い、モルティエレラ（Ｍｏｒｔｉｅｒｅ
ｌｌａ）属に属するアラキドン酸生産菌を、炭素源とし
てグルコース、窒素源として酵母エキスを用い、好まし
くは大豆油の存在下で培養し、アラキドン酸含有画分を
抽出、濃縮することにより、得ることができる。また、
特開平２−８６７８９号に開示の方法に従い、エントモ
フトラ（Ｅｎｔｏｍｏｐｈｔｈｏｒａ）属糸状菌を、有
機多塩基酸を添加した培地中で培養することにより、ア
ラキドン酸を菌体内に高濃度で蓄積させ、これを採取す
ることにより、迅速かつ安価に大量生産することもでき
る。[0008] fats and oils containing such relatively high concentrations of arachidonic acid, for example, in accordance with the method disclosed in JP 63-44891, Mortierella (Mortiere
lla ) An arachidonic acid-producing bacterium belonging to the genus is cultured by using glucose as a carbon source and yeast extract as a nitrogen source, preferably in the presence of soybean oil, and extracting and concentrating an arachidonic acid-containing fraction. Can be. Also,
According to the method disclosed in JP-A-2-86789, a fungus of the genus Entomophthora is cultured in a medium to which an organic polybasic acid has been added, so that arachidonic acid is accumulated at a high concentration in the cells. By collecting, mass production can be performed quickly and inexpensively.
【０００９】本発明の医薬組成物および健康食品は、か
かる比較的高濃度のアラキドン酸を含有する油脂単独ま
たはそれらの混合物のみで構成してもよく、あるいは、
このようなアラキドン酸含有油脂に加えて、ドコサヘキ
サエン酸（以下、ＤＨＡという）や、エイコサペンタエ
ン酸（以下、ＥＰＡという）、γ−リノレン酸、α−リ
ノレン酸、リノール酸、これらの酸を含有する油脂、例
えば、大豆油、ゴマ油、精製魚油など、また、ｄ−α−
トコフェロールなどのビタミン、カキ肉エキスなどのア
ミノ酸、および医薬上許容される賦形剤、担体など、ま
たは、甘味料、香辛料などの調味料などを適宜含有させ
てもよい。[0009] The pharmaceutical composition and health food of the present invention may be composed solely of a fat or oil containing such a relatively high concentration of arachidonic acid or a mixture thereof alone, or
In addition to such arachidonic acid-containing fats and oils, it contains docosahexaenoic acid (hereinafter, referred to as DHA), eicosapentaenoic acid (hereinafter, referred to as EPA), γ-linolenic acid, α-linolenic acid, linoleic acid, and these acids. Fats and oils, for example, soybean oil, sesame oil, refined fish oil, etc., and d-α-
Vitamins such as tocopherol, amino acids such as oyster meat extract, and pharmaceutically acceptable excipients and carriers, or seasonings such as sweeteners and spices may be appropriately contained.
【００１０】特に、アラキドン酸と共に、ＤＨＡを含有
させることにより、アラキドン酸の体内での働きが促進
され、その医薬組成物および健康食品としての効用がさ
らに向上することが判明した。一般に、ＤＨＡは、アラ
キドン酸に対する重量比で、０.５〜１.５倍の割合で添
加することにより良好な治療効果が得られる。[0010] In particular, it has been found that the inclusion of DHA together with arachidonic acid promotes the action of arachidonic acid in the body and further enhances its utility as a pharmaceutical composition and health food. In general, a good therapeutic effect can be obtained by adding DHA at a ratio of 0.5 to 1.5 times by weight relative to arachidonic acid.
【００１１】また、アラキドン酸と共に、カキ肉エキス
を含有させることにより、脂肪酸とアミノ酸の両方を摂
取でき、より一層の効用を期待できる。アラキドン酸含
有油脂とカキ肉エキスは混合物とする以外に、それぞれ
単独で同時にまたは順次に摂取するものとすることもで
きる。一般に、カキ肉エキスは、アラキドン酸に対する
重量比で、２〜１５０倍、好ましくは１５〜５０倍の割
合で添加するとより良好な予防・治療効果が得られる。[0011] Further, by containing oyster meat extract together with arachidonic acid, both fatty acids and amino acids can be ingested, and further effects can be expected. The arachidonic acid-containing oil and fat and the oyster meat extract may be taken alone or simultaneously or separately in addition to a mixture. In general, better prevention and treatment effects can be obtained by adding the oyster meat extract at a weight ratio of 2 to 150 times, preferably 15 to 50 times, relative to arachidonic acid.
【００１２】本発明の医薬組成物および健康食品は、常
法により、油剤、エマルジョン、ソフトカプセル剤、ハ
ードカプセル剤、錠剤、顆粒剤、固形剤、チュアブル
剤、ドレッシング類、菓子類などの形態にすることがで
きる。各成分を全てこれらの形態に含有させる以外に、
アラキドン酸含有油脂、ドコサヘキサエン酸含有油脂お
よびカキ肉エキスを各々独立して前記形態としたものを
種々に組み合わせたもの、あるいはアラキドン酸含有油
脂およびドコサヘキサエン酸含有油脂を含む前記形態と
カキ肉エキスを含む前記形態を組み合わせたもの、例え
ば、アラキドン酸含有油脂およびドコサヘキサエン酸含
有油脂を含むソフトカプセル剤およびカキ肉エキスを含
む錠剤よりなるキットや、アラキドン酸含有油脂を含む
ソフトカプセル剤およびカキ肉エキスを含む錠剤よりな
るキットの形態とすることもできる。また、本発明の医
薬組成物および健康食品は、ヒトに限らず、イヌ、ネ
コ、ラット、ネズミ、モルモット、サル、ヒヒなどの哺
乳動物の医薬組成物または飼料としてもよく、例えば、
常法に従い、飼料用の固体または液体の添加剤とするこ
ともできる。かかる、医薬組成物または飼料も本発明の
医薬組成物および健康食品に包含される。The pharmaceutical composition and health food of the present invention can be made into oils, emulsions, soft capsules, hard capsules, tablets, granules, solids, chewables, dressings, confectionery, etc. by a conventional method. Can be. In addition to containing all the components in these forms,
Arachidonic acid-containing fats and oils, and docosahexaenoic acid-containing oils and oyster meat extracts are each independently combined in various forms, or arachidonic acid-containing fats and docosahexaenoic acid-containing fats and oils, and the oyster meat extract is included. A combination of the above forms, for example, a kit comprising a soft capsule containing arachidonic acid-containing oil and fat and a docosahexaenoic acid-containing oil and a tablet containing oyster meat extract, and a soft capsule containing arachidonic acid-containing oil and fat and a tablet containing oyster meat extract In the form of a kit. Further, the pharmaceutical composition and health food of the present invention is not limited to humans, and may be a pharmaceutical composition or feed for mammals such as dogs, cats, rats, rats, guinea pigs, monkeys, baboons, and the like.
According to a conventional method, a solid or liquid additive for feed can be used. Such a pharmaceutical composition or feed is also included in the pharmaceutical composition and health food of the present invention.
【００１３】本発明の医薬組成物および健康食品は、通
常、アラキドン酸の１日の摂取量が成人の場合、５０〜
２,０００ｍｇ／日、好ましくは４００〜１,０００ｍｇ
／日となるように使用する。また、ヒト以外の哺乳動物
については、アラキドン酸の１日の摂取量が１〜５０ｍ
ｇ／ｋｇ、好ましくは５〜１０ｍｇ／ｋｇとなるように
与える。これにより、糖尿病、肝ガンなどに対して顕著
な予防・治療効果が得られる。[0013] The pharmaceutical composition and health food of the present invention usually have an arachidonic acid daily intake of 50 to 50% for an adult.
2,000 mg / day, preferably 400 to 1,000 mg
/ Day. For mammals other than humans, the daily intake of arachidonic acid is 1 to 50 m.
g / kg, preferably 5 to 10 mg / kg. As a result, remarkable preventive and therapeutic effects are obtained for diabetes, liver cancer, and the like.
【００１４】[0014]
【実施例】以下に実施例および実験例を挙げて本発明を
さらに詳しく説明するが、本発明はこれらに限定される
ものではない。なお、実施例中の「％」は「重量％」を
意味する。EXAMPLES The present invention will be described in more detail with reference to the following Examples and Experimental Examples, but the present invention is not limited thereto. In the examples, “%” means “% by weight”.
【００１５】実施例１ 以下の処方により、常法に従って、ソフトカプセル剤を
製造した。 成 分 配合量 アラキドン酸含有油脂 ５０．０％ （アラキドン酸を２２％以上含有） エイコサペンタエン酸（ＥＰＡ）含有精製魚油 １８．５％ （ＥＰＡを２８％以上、ＤＨＡを１２％以上含有） ドコサヘキサエン酸（ＤＨＡ）含有精製魚油 ３０．０％ （ＥＰＡを８％以上、ＤＨＡを３０％以上含有） ビタミンＥ抽出液 １．５％Example 1 A soft capsule was produced according to the following formulation according to a conventional method. Ingredients Compounding amount Arachidonic acid-containing oil and fat 50.0% (Arachidonic acid 22% or more) Eicosapentaenoic acid (EPA) -containing purified fish oil 18.5% (EPA 28% or more, DHA 12% or more) Docosahexaenoic acid (DHA) -containing purified fish oil 30.0% (containing 8% or more of EPA and 30% or more of DHA) Vitamin E extract 1.5%
【００１６】実施例２ 以下の処方により、常法に従って、ドレッシングを製造
した。 Example 2 A dressing was produced according to the following formulation according to a conventional method.
【００１７】実施例３ まず、以下の処方により、常法に従って、アラキドン酸
粉末を調製した。 Example 3 First, arachidonic acid powder was prepared according to the following formulation according to a conventional method.
【００１８】アラキドン酸含有油脂を溶媒のエタノール
に溶解し、残りの原料を混合したものに、この溶液を添
加し、混合分散させて吸着させた後、加温乾燥して溶媒
を除去し、アラキドン酸粉末とした。こうして得られた
アラキドン酸粉末を用い、以下の処方により、常法に従
って、ハードカプセル剤を製造した。 The arachidonic acid-containing oil or fat is dissolved in ethanol as a solvent, and this solution is added to a mixture of the remaining raw materials, mixed, dispersed and adsorbed, and then heated and dried to remove the solvent. Acid powder. Using the arachidonic acid powder thus obtained, hard capsules were produced according to the following formulation according to a conventional method.
【００１９】実施例４ 実施例３で調製したアラキドン酸粉末を用い、以下の処
方により、常法に従って、錠剤を製造した。 成 分 配合量（ｍｇ） カキ肉エキスまたはカキ抽出物 １００.０ アラキドン酸粉末 １００.０ 結晶セルロース ２０.０ ショ糖エステル １０.０ セラック １２.９ 白糖 １５０.０ タルク ０.７ 炭酸カルシウム ２.５ 乳糖 ９３.５ 着色料（酸化チタン） ０.６ 増粘料（プルラン） ０.２ ゼラチン ５.８ アラビアゴム １.１ 粉末油脂 ０.１ カラメル色素 １.８Example 4 A tablet was produced from the arachidonic acid powder prepared in Example 3 according to the following formulation and according to a conventional method. Ingredients Blended amount (mg) Oyster meat extract or oyster extract 100.0 Arachidonic acid powder 100.0 Crystalline cellulose 20.0 Sucrose ester 10.0 Shellac 12.9 Sucrose 15.0 Talc 0.7 Calcium carbonate 2. 5 Lactose 93.5 Colorant (Titanium oxide) 0.6 Thickener (Pullulan) 0.2 Gelatin 5.8 Gum arabic 1.1 Powdered fat 0.1 Caramel pigment 1.8
【００２０】実施例５ 以下の処方により、常法に従って、アラキドン酸含有油
脂およびドコサヘキサエン酸含有油脂を含むソフトゼラ
チンカプセル剤を調製した。 成 分 配合量 （一粒250mg当たり） アラキドン酸含有油脂 １０９.２５ｍｇ （アラキドン酸を３７％以上含有） エイコサペンタエン酸（ＥＰＡ）含有精製魚油 ８０.２５ｍｇ （ＥＰＡを２８％以上、ＤＨＡを１２％以上含有） ドコサヘキサエン酸（ＤＨＡ）含有精製魚油 ６０.００ｍｇ （ＥＰＡを５％以上、ＤＨＡを２７％以上含有） ビタミンＥ抽出液 ０.５０ｍｇ （ビタミンＥを４５％含有） また、以下の処方により、カキ肉エキスを含む錠剤を調製した。 成 分 配合量 （一粒450mg当たり） カキ肉エキスまたはカキ抽出物 ２００.０ｍｇ 結晶セルロース ２０.０ｍｇ ショ糖脂肪酸エステル １０.０ｍｇ 白糖 １２２.３ｍｇ 乳糖 ７６.３ｍｇ セラック １０.６ｍｇ ゼラチン ４.８ｍｇ 炭酸カルシウム ２.２ｍｇ以下 カラメル色素 ２.２ｍｇ以下 アラビアゴム ２.２ｍｇ以下 タルク ２.２ｍｇ以下 着色料（二酸化チタン） ２.２ｍｇ以下 増粘剤（プルラン） ２.２ｍｇ以下 粉末油脂 ２.２ｍｇ以下 ＰＴＰ包装により両剤を組合わせてキットを得た。Example 5 Soft gelatin capsules containing arachidonic acid-containing fats and oils and docosahexaenoic acid-containing fats and oils were prepared according to the following formulation according to a conventional method. Ingredients Amount (per 250mg) Arachidonic acid-containing oil and fat 109.25mg (Archidonic acid 37% or more) Eicosapentaenoic acid (EPA) -containing purified fish oil 80.25mg (EPA 28% or more, DHA 12% or more) Contained) docosahexaenoic acid (DHA) -containing purified fish oil 60.00 mg (containing 5% or more of EPA and 27% or more of DHA) Vitamin E extract 0.50 mg (containing 45% of vitamin E) Tablets containing the meat extract were prepared. Ingredients Amount (per 450 mg) Oyster meat extract or oyster extract 20.0 mg Crystalline cellulose 20.0 mg Sucrose fatty acid ester 10.0 mg Sucrose 122.3 mg Lactose 76.3 mg Shellac 10.6 mg Gelatin 4.8 mg Calcium carbonate 2.2 mg or less Caramel pigment 2.2 mg or less Arabic gum 2.2 mg or less Talc 2.2 mg or less Colorant (titanium dioxide) 2.2 mg or less Thickener (Pullulan) 2.2 mg or less Powdered fat 2.2 mg or less PTP packaging A kit was obtained by combining both agents.
【００２１】実験例１ 実施例１の処方で調製されたソフトゼラチンカプセル剤
の中身を用いて癌細胞への効果を実験した。ＡＨ−１３
０肝癌細胞をソフトゼラチンカプセルの中身と共に２４
時間培養した。トリパンブルー排除試験により死亡細胞
を染色し、死癌細胞％を求めた。また、細胞膜およびミ
クロソームのリン脂質中のアラキドン酸含量を測定し
た。結果を表１に示す。Experimental Example 1 The effect on cancer cells was tested using the contents of the soft gelatin capsule prepared according to the formulation of Example 1. AH-13
0 Liver cancer cells along with soft gelatin capsule contents 24
Cultured for hours. Dead cells were stained by trypan blue exclusion test to determine the percentage of dead cancer cells. In addition, the arachidonic acid content in cell membrane and microsome phospholipids was measured. Table 1 shows the results.
【００２２】[0022]
【表１】 [Table 1]
【００２３】表１より、肝癌細胞にアラキドン酸を添加
することで癌細胞の死数が増え、また肝癌時に不足する
リン脂質中のアラキドン酸量も増加することが分かる。From Table 1, it can be seen that the addition of arachidonic acid to liver cancer cells increases the number of cancer cell deaths and also increases the amount of arachidonic acid in phospholipids deficient in liver cancer.
【００２４】実験例２ 実施例３の処方で調製されたアラキドン酸粉末を用い
て、糖尿病の改善を試みた。１６日齢のSprague-Dawley
ラット（１２０−１３０ｇ）を用いて、６５ｍｇ／ｋｇ
ストレプトゾトシンを皮下注射し、糖尿病ラットを作成
した。ラットに高脂肪食（主にバター）を与え、その半
数にアラキドン酸換算量１５０ｍｇ／週を与えた。４週
間後、euglycemic-hyperinsulinemic clampを用いてイ
ンスリン感受性を調べ、さらに肝臓リン脂質中脂肪酸
（％）を測定した。また、インスリン注射（３ｍＵ／ｍ
ｉｎ／ｋｇ）をし、同様に測定した。結果を表２に示
す。Experimental Example 2 An attempt was made to improve diabetes using the arachidonic acid powder prepared according to the formulation of Example 3. 16-day-old Sprague-Dawley
Using rats (120-130 g), 65 mg / kg
Streptozotocin was injected subcutaneously to produce diabetic rats. Rats were fed a high fat diet (mainly butter), and half of them were given an arachidonic acid equivalent of 150 mg / week. Four weeks later, insulin sensitivity was examined using an euglycemic-hyperinsulinemic clamp, and fatty acid (%) in liver phospholipids was measured. Insulin injection (3 mU / m
in / kg) and measured similarly. Table 2 shows the results.
【００２５】[0025]
【表２】 [Table 2]
【００２６】表２から分かるように、アラキドン酸粉末
添加で糖尿病で見られるアラキドン酸不足を補い、イン
スリン存在下でインスリンの作用が増大される。つま
り、インスリンが存在するＩＩ型（インスリン非依存
型）糖尿病、もしくはインスリン治療中Ｉ型（インスリ
ン依存型）糖尿病に有効と言える。As can be seen from Table 2, the addition of arachidonic acid powder compensates for arachidonic acid deficiency seen in diabetes and increases the action of insulin in the presence of insulin. In other words, it can be said that the present invention is effective for type II (insulin-independent) diabetes in which insulin is present, or type I (insulin-dependent) diabetes during insulin treatment.
【００２７】実施例４の処方によって調製した錠剤を用
いて投与実験を行い、血漿中アラキドン酸量を測定し
た。６週齢ＳＤラットにラード、アラキドン酸、または
アラキドン酸とカキ肉エキス含有飼料をそれぞれ投与
し、２週間後、血中アラキドン酸量を測定した。結果を
表３に示す。An administration experiment was conducted using the tablets prepared according to the formulation of Example 4, and the amount of arachidonic acid in plasma was measured. Lard, arachidonic acid, or a feed containing arachidonic acid and oyster meat extract were respectively administered to 6-week-old SD rats, and two weeks later, the blood arachidonic acid level was measured. Table 3 shows the results.
【００２８】[0028]
【表３】 [Table 3]
【００２９】カキ肉エキスの有無によるアラキドン酸の
血中量を比べると、カキ肉エキス含有の方が吸収率がよ
いことが分かる。Comparing the blood levels of arachidonic acid with and without the oyster extract, it can be seen that the absorption rate is better with the oyster extract.
【００３０】[0030]
【発明の効果】本発明によれば、安価に大量生産可能な
アラキドン酸含有油脂を含有し、糖尿病や肝ガンなどの
肝疾患を実用的かつ有効に予防・治療し得る医薬組成物
および健康食品が得られる。Industrial Applicability According to the present invention, a pharmaceutical composition and a health food containing arachidonic acid-containing fats and oils which can be mass-produced at low cost and which can practically and effectively prevent and treat liver diseases such as diabetes and liver cancer. Is obtained.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 9/48 Ａ６１Ｋ 9/48 Ｆ 31/00 ６０３ 31/00 ６０３Ｎ 35/56 35/56 (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 31/20 A23K 1/16 301 A23L 1/30 A61K 9/20 A61K 9/48 A61K 35/56 ＣＡ（ＳＴＮ) ＭＥＤＬＩＮＥ（ＳＴＮ)──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 9/48 A61K 9/48 F 31/00 603 31/00 603N 35/56 35/56 (58) Fields surveyed (Int. Cl. 6 , DB name) A61K 31/20 A23K 1/16 301 A23L 1/30 A61K 9/20 A61K 9/48 A61K 35/56 CA (STN) MEDLINE (STN)
Claims (18)
なることを特徴とする糖尿病の予防または治療用の医薬
組成物。1. A pharmaceutical composition for preventing or treating diabetes, comprising an arachidonic acid-containing fat or oil as an essential component.
む請求項１記載の医薬組成物。2. The pharmaceutical composition according to claim 1, further comprising a fat containing docosahexaenoic acid.
の医薬組成物。3. The pharmaceutical composition according to claim 1, further comprising an oyster extract.
の医薬組成物。4. The pharmaceutical composition according to claim 2, further comprising an oyster meat extract.
ン酸含有量に対して、０.５〜１０倍である請求項２ま
たは４記載の医薬組成物。5. The pharmaceutical composition according to claim 2, wherein the content of docosahexaenoic acid is 0.5 to 10 times the content of arachidonic acid.
る請求項１〜５いずれか１項記載の医薬組成物。6. The pharmaceutical composition according to claim 1, which is in the form of a soft capsule or a tablet.
項２記載の医薬組成物。7. The pharmaceutical composition according to claim 2, which is further combined with an oyster meat extract.
ン酸含有量に対して、０.５−１０倍である請求項７記
載の医薬組成物。8. The pharmaceutical composition according to claim 7, wherein the content of docosahexaenoic acid is 0.5 to 10 times the content of arachidonic acid.
セル剤およびカキ肉エキスを含む錠剤を組み合わせてな
る請求項７または８記載の医薬組成物。9. The pharmaceutical composition according to claim 7, wherein a soft capsule containing arachidonic acid-containing oil and fat and a tablet containing oyster meat extract are combined.
てなることを特徴とする糖尿病の予防または治療用の健
康食品。10. A health food for preventing or treating diabetes, comprising an arachidonic acid-containing oil or fat as an essential component.
含む請求項１０記載の健康食品。11. The health food according to claim 10, further comprising docosahexaenoic acid-containing fat or oil.
記載の健康食品。12. The method according to claim 10, further comprising an oyster meat extract.
Health food as described.
記載の健康食品。13. The method according to claim 11, further comprising an oyster extract.
Health food as described.
ドン酸含有量に対して、０.５〜１０倍である請求項１
１または１３記載の健康食品。14. The docosahexaenoic acid content is 0.5 to 10 times the arachidonic acid content.
14. The health food according to 1 or 13.
ある請求項１０〜１３いずれか１項記載の健康食品。15. The health food according to claim 10, which is in the form of a soft capsule or a tablet.
求項１１記載の健康食品。16. The health food according to claim 11, which is further combined with an oyster meat extract.
ドン酸含有量に対して、０.５−１０倍である請求項１
６記載の健康食品。17. The docosahexaenoic acid content is 0.5 to 10 times the arachidonic acid content.
6. The health food according to 6.
プセル剤およびカキ肉エキスを含む錠剤を組み合わせて
なる請求項１６または１７記載の健康食品。18. The health food according to claim 16, wherein a soft capsule containing arachidonic acid-containing oil and fat and a tablet containing oyster meat extract are combined.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10177056A JP2941787B2 (en) | 1997-08-14 | 1998-06-24 | Pharmaceutical composition and health food containing polyunsaturated fatty acid |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9-219546 | 1997-08-14 | ||
| JP21954697 | 1997-08-14 | ||
| JP10177056A JP2941787B2 (en) | 1997-08-14 | 1998-06-24 | Pharmaceutical composition and health food containing polyunsaturated fatty acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09642999A Division JP3947322B2 (en) | 1997-08-14 | 1999-04-02 | Pharmaceutical composition and health food containing polyunsaturated fatty acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11116473A JPH11116473A (en) | 1999-04-27 |
| JP2941787B2 true JP2941787B2 (en) | 1999-08-30 |
Family
ID=26497732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10177056A Expired - Fee Related JP2941787B2 (en) | 1997-08-14 | 1998-06-24 | Pharmaceutical composition and health food containing polyunsaturated fatty acid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2941787B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4721642B2 (en) | 2004-01-20 | 2011-07-13 | サントリーホールディングス株式会社 | Preventive or ameliorating agent for liver diseases associated with liver damage |
| JP2006327996A (en) * | 2005-05-27 | 2006-12-07 | Sonoko:Kk | Medicine or functional food for controlling elevation of glycemia |
| JP6334482B2 (en) * | 2015-08-28 | 2018-05-30 | 中野Ｂｃ株式会社 | Solid agent and production method thereof |
-
1998
- 1998-06-24 JP JP10177056A patent/JP2941787B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11116473A (en) | 1999-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1296670B1 (en) | Therapeutic combinations of fatty acids | |
| KR101344053B1 (en) | Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions | |
| EP2258377B1 (en) | Glycerophospholipids containing omega-3 and omega-6 fatty acids | |
| JP4771697B2 (en) | Composition having an effect of preventing, improving or improving the normal response of cognitive ability | |
| DE69634655T2 (en) | Use of a physiologically functional food to improve and / or strengthen brain function, learning ability and memory function | |
| US20150182486A1 (en) | COMPOSITION CONTAINING DIHOMO-y-LINOLENIC ACID (DGLA) AS THE ACTIVE INGREDIENT | |
| JP2015212266A (en) | Glycerophospholipids for improvement of cognitive functions | |
| WO2008149177A2 (en) | Marine lipid compositions and uses thereof | |
| KR20040026697A (en) | Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction | |
| IE891819L (en) | Essential fatty acid compositions | |
| EP1174416A1 (en) | Conjugated fatty acid esters | |
| JP2021508343A (en) | Lysophosphatidylcholine composition | |
| US20090099261A1 (en) | Omega-3 mixtures | |
| DE69523759T3 (en) | PREPARATIONS OF NERVONIC ACID | |
| JP6150735B2 (en) | Nerve regeneration agent | |
| JP2677949B2 (en) | Health food containing arachidonic acid | |
| JP2941787B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
| JP3947322B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
| JPH06271464A (en) | Arachidonic acid-containing composition for prevention or improvement of alimentary disorder | |
| JP6842093B2 (en) | Learning memory enhancer | |
| JP5759663B2 (en) | Skin barrier function improver, etc. | |
| JPH05163142A (en) | Arachidonic acid-containing composition for preventing and treating liver disease | |
| JP2016172770A (en) | Composition having ameliorating action on reduction in higher brain function caused by brain structural disorder | |
| JP6095615B2 (en) | Composition having an improving effect on lowering of higher brain function due to organic brain injury | |
| JP2000086425A (en) | Skin-whitening agent and skin whitening composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19990518 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090618 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100618 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100618 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110618 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120618 Year of fee payment: 13 |
|
| LAPS | Cancellation because of no payment of annual fees |